We are live on ! Find out more
IFRX icon

InflaRx

33 hedge funds and large institutions have $17.7M invested in InflaRx in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,557% more call options, than puts

Call options by funds: $256K | Put options by funds: $7K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

18% more funds holding

Funds holding: 2833 (+5)

16% more capital invested

Capital invested by funds: $15.3M → $17.7M (+$2.4M)

0.34% less ownership

Funds ownership: 13.8%13.46% (-0.34%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
33
Holders Change
+5
Holders Change %
+17.86%
% of All Funds
0.58%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
7
Reduced
8
Closed
6
Calls
$256K
Puts
$7K
Net Calls
+$249K
Net Calls Change
-$109K

IFRX Hedge Fund Activity: Q4 2020 in Review

33 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q4 2020, worth a combined $17.7M — up 16% from $15.3M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new IFRX positions and 6 closed out — a net gain of 5 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Bank Julius Baer & Co, opening a new position worth an estimated $889K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $798K.

  • 33 institutional investors held InflaRx (IFRX) as of Q4 2020, up from 28 in Q3 2020.
  • Funds reported $17.7M of InflaRx stock for Q4 2020, up 16% quarter-over-quarter.
  • 11 funds opened new InflaRx positions in Q4 2020 and 6 closed out, a net change of +5 holders.
  • The largest InflaRx buyer in Q4 2020 was Bank Julius Baer & Co, an estimated $889K added.
  • The largest InflaRx seller in Q4 2020 was Schonfeld Strategic Advisors, an estimated $798K sold.

Based on aggregated 13F filings for Q4 2020.